Slideshow
-
Opdivo (rev 8/17) slide 1
-
Opdivo (rev 8/17) slide 2
-
Opdivo (rev 8/17) slide 3
-
Opdivo (rev 8/17) slide 4
-
Opdivo (rev 8/17) slide 5
-
Opdivo (rev 8/17) slide 6
-
Opdivo (rev 8/17) slide 7
-
Opdivo (rev 8/17) slide 8
-
Opdivo (rev 8/17) slide 9
-
Opdivo (rev 8/17) slide 10
-
Opdivo (rev 8/17) slide 11
-
Opdivo (rev 8/17) slide 12
-
Opdivo (rev 8/17) slide 13
-
Opdivo (rev 8/17) slide 14
-
Opdivo (rev 8/17) slide 15
-
Opdivo (rev 8/17) slide 16
-
Opdivo (rev 8/17) slide 17
-
Opdivo (rev 8/17) slide 18
-
Opdivo (rev 8/17) slide 19
-
Opdivo (rev 8/17) slide 20
-
Opdivo (rev 8/17) slide 21
-
Opdivo (rev 8/17) slide 22
-
Opdivo (rev 8/17) slide 23
-
Opdivo (rev 8/17) slide 24
-
Opdivo (rev 8/17) slide 25
-
Opdivo (rev 8/17) slide 26
-
Opdivo (rev 8/17) slide 27
-
Opdivo (rev 8/17) slide 28
-
Opdivo (rev 8/17) slide 29
-
Opdivo (rev 8/17) slide 30
-
Opdivo (rev 8/17) slide 31
-
Opdivo (rev 8/17) slide 32
-
Opdivo (rev 8/17) slide 33
-
Opdivo (rev 8/17) slide 34
-
Opdivo (rev 8/17) slide 35
-
Opdivo (rev 8/17) slide 36
-
Opdivo (rev 8/17) slide 37
This slideshow examines nivolumab (Opdivo), indicated for the treatment of patients with Metastatic non-small cell lung cancer, advanced renal cell carcinoma, and classical Hodgkin lymphoma.
Table of Contents
Slide 5: Dosage and Administration
Slide 15: Cautions, Effects, and Interactions
Slide 26: What to Tell Your Patient
Slide 35: Reference
